Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya.
HIV
Hepatitis C (HCV)
Persons who inject drugs (PWID)
Sub-Saharan Africa (SSA)
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
21 Jan 2022
21 Jan 2022
Historique:
received:
03
09
2021
accepted:
05
01
2022
entrez:
22
1
2022
pubmed:
23
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
Persons who inject drugs (PWID) have higher HIV and hepatitis C virus (HCV) seroprevalence than the general population in many parts of sub-Saharan Africa (SSA). The seroprevalences of HIV and HCV are also higher in coastal Kenya than in Nairobi. Understanding drivers of regional HIV and HCV variation among PWID in Kenya may inform population-specific prevention interventions. Using a cross-sectional study, we defined HIV and HCV seroprevalence among persons identified as sexual or injecting partners of HIV positive PWID in two regions of Kenya and used logistic regression to identify demographic and behavioral characteristics associated with higher seroprevalence. Among 2386 partners, 469 (19.7%) tested HIV positive and 297(12.4%) tested HCV antibody positive. Partners on the Coast were more likely to live with HIV (seroprevalences: Coast = 23.8%, Nairobi = 17.1%; p < 0.001) and be HCV antibody positive (seroprevalences: Coast = 17.0%, Nairobi = 8.6%; p < 0.001). After adjusting for sex, age, and years injecting and accounting for clustering by site, the higher prevalence of both diseases in the Coast remained significant for HIV (OR 1.68, 95% CI 1.13-2.51) but not for HCV (OR 1.72, 95% CI 0.84-3.74). Compared to those recruited in Nairobi, partners on the Coast were older (Coast = 35 years, Nairobi = 31 years; p < 0.001), more likely to be male (Coast = 77.6%, Nairobi = 61.7%; p < 0.001), to have paid (Coast = 59.2%, Nairobi = 32.8%; p < 0.001) or received (Coast = 44.2%, Nairobi 35.4%; p < 0.001) money for sex, or to have had sex with someone they knew to be HIV positive (Coast 22.0%, Nairobi 10.8%; p < 0.001). Partners who had injected for five or more years had 1.48 times greater odds (95% CI 1.20-1.82) of living with HIV compared to partners who injected less than 5 years and more than twice the odds of HCV (95% CI 1.84-4.11). HIV and HCV seroprevalence among sexual and injecting partners of PWID was, respectively, 5 times and > 12 times greater than is reported among the general population in Kenya (4% and < 1%, respectively). Providing resources and education will be crucial to reduce exposure and to maintain the lower needle and equipment sharing that we observed compared to other studies.
Sections du résumé
BACKGROUND
BACKGROUND
Persons who inject drugs (PWID) have higher HIV and hepatitis C virus (HCV) seroprevalence than the general population in many parts of sub-Saharan Africa (SSA). The seroprevalences of HIV and HCV are also higher in coastal Kenya than in Nairobi. Understanding drivers of regional HIV and HCV variation among PWID in Kenya may inform population-specific prevention interventions.
METHODS
METHODS
Using a cross-sectional study, we defined HIV and HCV seroprevalence among persons identified as sexual or injecting partners of HIV positive PWID in two regions of Kenya and used logistic regression to identify demographic and behavioral characteristics associated with higher seroprevalence.
RESULTS
RESULTS
Among 2386 partners, 469 (19.7%) tested HIV positive and 297(12.4%) tested HCV antibody positive. Partners on the Coast were more likely to live with HIV (seroprevalences: Coast = 23.8%, Nairobi = 17.1%; p < 0.001) and be HCV antibody positive (seroprevalences: Coast = 17.0%, Nairobi = 8.6%; p < 0.001). After adjusting for sex, age, and years injecting and accounting for clustering by site, the higher prevalence of both diseases in the Coast remained significant for HIV (OR 1.68, 95% CI 1.13-2.51) but not for HCV (OR 1.72, 95% CI 0.84-3.74). Compared to those recruited in Nairobi, partners on the Coast were older (Coast = 35 years, Nairobi = 31 years; p < 0.001), more likely to be male (Coast = 77.6%, Nairobi = 61.7%; p < 0.001), to have paid (Coast = 59.2%, Nairobi = 32.8%; p < 0.001) or received (Coast = 44.2%, Nairobi 35.4%; p < 0.001) money for sex, or to have had sex with someone they knew to be HIV positive (Coast 22.0%, Nairobi 10.8%; p < 0.001). Partners who had injected for five or more years had 1.48 times greater odds (95% CI 1.20-1.82) of living with HIV compared to partners who injected less than 5 years and more than twice the odds of HCV (95% CI 1.84-4.11).
CONCLUSION
CONCLUSIONS
HIV and HCV seroprevalence among sexual and injecting partners of PWID was, respectively, 5 times and > 12 times greater than is reported among the general population in Kenya (4% and < 1%, respectively). Providing resources and education will be crucial to reduce exposure and to maintain the lower needle and equipment sharing that we observed compared to other studies.
Identifiants
pubmed: 35062890
doi: 10.1186/s12879-022-07036-8
pii: 10.1186/s12879-022-07036-8
pmc: PMC8780315
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73Subventions
Organisme : NIMH NIH HHS
ID : T32 MH019105
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA043409
Pays : United States
Organisme : FIC NIH HHS
ID : D43TW009580
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM081062
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Semin Diagn Pathol. 2017 Jul;34(4):314-317
pubmed: 28566241
N Engl J Med. 2001 Jul 5;345(1):41-52
pubmed: 11439948
Drug Alcohol Depend. 2004 Aug 16;75(2):177-83
pubmed: 15276223
BMJ Open. 2021 Apr 24;11(4):e041083
pubmed: 33895711
J Acquir Immune Defic Syndr (1988). 1994 May;7(5):500-3
pubmed: 8158545
AIDS Care. 2018 Oct;30(10):1290-1297
pubmed: 29558813
Sex Transm Infect. 2013 Nov;89 Suppl 3:iii41-4
pubmed: 24064986
AIDS Behav. 2015 Jul;19(7):1327-37
pubmed: 25626889
J Viral Hepat. 2003 Sep;10(5):394-400
pubmed: 12969192
Lancet Infect Dis. 2019 Nov;19(11):1255-1263
pubmed: 31540840
Subst Use Misuse. 2005;40(1):99-123
pubmed: 15702651
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
Drug Alcohol Depend. 2011 Dec 1;119(1-2):138-41
pubmed: 21700402
Lancet Infect Dis. 2002 May;2(5):293-302
pubmed: 12062995
Lancet. 2008 Nov 15;372(9651):1733-45
pubmed: 18817968
Harm Reduct J. 2009 Aug 28;6:24
pubmed: 19715601
J Infect Dis. 2019 Jun 5;220(1):78-90
pubmed: 30726973
J Infect Dis. 2000 Dec;182(6):1588-94
pubmed: 11069228
Pan Afr Med J. 2013;14:44
pubmed: 23560127
PLoS One. 2017 May 19;12(5):e0177341
pubmed: 28542351
Harm Reduct J. 2005 Aug 25;2:12
pubmed: 16122382
Int J Epidemiol. 2012 Apr;41(2):514-20
pubmed: 22253321
BMJ Open. 2015 Mar 06;5(3):e007198
pubmed: 25748417
J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):420-7
pubmed: 26226249
Int J Drug Policy. 2014 Nov;25(6):1195-203
pubmed: 24556208